Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia

AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) forthe treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.
Läs mer